Juan Aguilar-Company

Vall d´Hebron Institut d´Oncologia

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (15)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (12)

Marco Tagliamento

Researcher/Assistant Professor

University of Genoa

ITALY

View details

Paolo Pedrazzoli

Professor of Oncology

Università degli Studi di Pavia

ITALY

View details

Wieland Meyer

University of Sydney

AUSTRALIA

View details

Nadia Harbeck

GERMANY

View details

Lee Cooper

University Hospital

UNITED KINGDOM

View details

Javier Gavira Díaz

Institut Català d'Oncologia

SPAIN

View details

Alberto Zambelli

Humanitas University

ITALY

View details

Cian Murphy

The Francis Crick Institute

UNITED KINGDOM

View details

Mark Bower

Professor

Chelsea and Westminster Hospital

UNITED KINGDOM

View details

Matteo Lambertini

University of Genova

ITALY

View details

Jasmine Handford

Database Manager for Head & Neck Cancer

King's College London - Guy's Campus

UNITED KINGDOM

View details

DANIELE GENERALI

University of Trieste

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Juan Aguilar-Company

Research Interests

Explore related searches

Contact this professor

Articles (15)

Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry

Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry

The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease

Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysis.

Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study.

Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer

Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry

Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry

Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer.

Multidisciplinary approach to treatment with immune checkpoint inhibitors in patients with HIV, tuberculosis, or underlying autoimmune diseases.

Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study.

Long-term treatment with nebulized colistin in oncological patients with recurrent respiratory infections.

Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry.

Pneumocystis jirovecii genetic diversity in a Spanish tertiary hospital

Collaborators (12)

Marco Tagliamento

Paolo Pedrazzoli

Wieland Meyer

Nadia Harbeck

Lee Cooper

Javier Gavira Díaz

Alberto Zambelli

Cian Murphy

Mark Bower

Matteo Lambertini

Jasmine Handford

DANIELE GENERALI

Make your next move.